Ocular Disease Therapeutics: Design and Delivery of Drugs for Diseases of the Eye

研究成果: 雜誌貢獻回顧型文獻同行評審

16 引文 斯高帕斯(Scopus)


The ocular drug discovery field has evidenced significant advancement in the past decade. The FDA approvals of Rhopressa, Vyzulta, and Roclatan for glaucoma, Brolucizumab for wet age-related macular degeneration (wet AMD), Luxturna for retinitis pigmentosa, Dextenza (0.4 mg dexamethasone intracanalicular insert) for ocular inflammation, ReSure sealant to seal corneal incisions, and Lifitegrast for dry eye represent some of the major developments in the field of ocular therapeutics. A literature survey also indicates that gene therapy, stem cell therapy, and target discovery through genomic research represent significant promise as potential strategies to achieve tissue repair or regeneration and to attain therapeutic benefits in ocular diseases. Overall, the emergence of new technologies coupled with first-in-class entries in ophthalmology are highly anticipated to restructure and boost the future trends in the field of ophthalmic drug discovery. This perspective focuses on various aspects of ocular drug discovery and the recent advances therein. Recent medicinal chemistry campaigns along with a brief overview of the structure-activity relationships of the diverse chemical classes and developments in ocular drug delivery (ODD) are presented.

頁(從 - 到)10533-10593
期刊Journal of Medicinal Chemistry
出版狀態接受/付印 - 2020

ASJC Scopus subject areas

  • 分子醫學
  • 藥物發現


深入研究「Ocular Disease Therapeutics: Design and Delivery of Drugs for Diseases of the Eye」主題。共同形成了獨特的指紋。